An interventional study of Silver nanoparticles and uncoated titanium miniscrews in Class I Malocclusion, Maxillary Prognathism and Orthodontic Tooth Movement, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 14 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
study will be directed to evaluate silver-hydroxyapatite nano-coated versus uncoated orthodontic miniscrews for en masse retraction of the upper anterior segment.
Silver-hydroxyapatite nanoparticles (Ag-HA NPs) have lately gained popularity in dentistry due to their unique combination of silver antibacterial activity and hydroxyapatite's osteoconductive, remineralizing characteristics. Ag-HA has shown potential in resolving two important clinical issues: infection control and anchoring stability. Coating orthodontic miniscrews with Ag-HA NPs has been demonstrated to reduce peri-implant biofilm growth by their antimicrobial effect, minimizing inflammation, and increasing osseointegration, thus increasing the long-term success of temporary anchoring devices (TADs).
35 studies on the registry are indexed under Malocclusion, Angle Class I; 10 are open to participants now.
This study's planned enrollment of 14 is below the median of 32 across 31 interventional studies indexed under Malocclusion, Angle Class I.
Browse Malocclusion, Angle Class I studies →Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive silver-hydroxyapatite nanocoated titanium miniscrews. These miniscrews will be placed in the maxillary bone for en masse retraction of the upper anterior teeth.
Device: Silver nanoparticles
Patients will receive conventional uncoated titanium miniscrews of the same dimensions and design as Arm 1, but without nano-coating.
Device: uncoated titanium miniscrews
Patients will receive silver-hydroxyapatite nanocoated titanium miniscrews.These miniscrews will be placed in the maxillary bone for en masse retractonof the upper anterior teeth.
Patients will receive conventional uncoated titanium miniscrews of the same dimensions and design as the intervention of the group1, but without nano-coating.
Assessment of the clinical and radiographically success rate of nanocoated versus uncoated orthodontic miniscrews after en masse retraction
Assessment of the clinical and radiographically success rate of nanocoated versus uncoated orthodontic miniscrews after en masse retraction
Time frame: about 6 months
Assessment of the rate of en masse retraction of the anterior segment of the upper arch
Assessment of the rate of en masse retraction of the anterior segment of the upper arch.
Time frame: 6 months
Plan to share: No — Data Will not be Shared Due to Privacy Consideration.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jun 2028, 25 months later.
Of 23 interventional studies with no phase under Malocclusion, Angle Class I, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 24. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.